Literature DB >> 2327765

In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics.

J W Gu1, H C Neu.   

Abstract

The in vitro activity of Ro 23-9424, which is desacetyl-cefotaxime linked to fleroxacin, was compared with the activities of cefotaxime, desacetyl-cefotaxime, fleroxacin, ofloxacin, and ciprofloxacin. It inhibited the majority of members of the family Enterobacteriaceae, except for some Serratia marcescens, Citrobacter freundii, and Enterobacter cloacae strains, at less than or equal to 0.25 microgram/ml and had an MIC for 90% of strains tested (MIC90) of 8 micrograms/ml against Pseudomonas aeruginosa. Most group A, B, C, and G streptococci and Streptococcus pneumoniae were inhibited at less than or equal to 0.25 microgram/ml. Ninety percent of the staphylococci were inhibited at less than or equal to 4 micrograms/ml, except for some methicillin-resistant Staphylococcus aureus isolates. The MIC90S of Ro 23-9424 for Enterococcus faecalis and Listeria monocytogenes were greater than or equal to 16 micrograms/ml. Ninety percent of Clostridium perfringens isolates were inhibited by less than or equal to 2 micrograms/ml, whereas Bacteroides fragilis had an MIC90 of 32 micrograms/ml. There was a minimal inoculum size effect. The MICs and MBCs were either identical or within a twofold dilution. The MICs of Ro 23-9424 for Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Enterobacter cloacae, Citrobacter freundii, Pseudomonas aeruginosa, and Staphylococcus aureus increased 16- to 128-fold after 2 weeks of transfer in the presence of Ro 23-9424, showing that the presence of two agents does not prevent resistance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2327765      PMCID: PMC171554          DOI: 10.1128/AAC.34.2.189

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  A new cephalosporin with a dual mode of action.

Authors:  C H O'Callaghan; R B Sykes; S E Staniforth
Journal:  Antimicrob Agents Chemother       Date:  1976-08       Impact factor: 5.191

2.  Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

3.  In vitro activities of a dual-action antibacterial agent, Ro 23-9424, and comparative agents.

Authors:  G Beskid; V Fallat; E R Lipschitz; D H McGarry; R Cleeland; K Chan; D D Keith; J Unowsky
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

4.  In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone.

Authors:  N X Chin; D C Brittain; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

5.  Mode of action of the dual-action cephalosporin Ro 23-9424.

Authors:  N H Georgopapadakou; A Bertasso; K K Chan; J S Chapman; R Cleeland; L M Cummings; B A Dix; D D Keith
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

  5 in total
  10 in total

1.  In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents.

Authors:  K V Rolston; H T Nguyen; D H Ho; B LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

2.  In vitro activity of Ro 23-9424 against clinical isolates of Legionella species.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

3.  A Hybrid Drug Limits Resistance by Evading the Action of the Multiple Antibiotic Resistance Pathway.

Authors:  Kathy K Wang; Laura K Stone; Tami D Lieberman; Michal Shavit; Timor Baasov; Roy Kishony
Journal:  Mol Biol Evol       Date:  2015-11-03       Impact factor: 16.240

4.  Dual-Pharmacophore Pyrithione-Containing Cephalosporins Kill Both Replicating and Nonreplicating Mycobacterium tuberculosis.

Authors:  Landys Lopez Quezada; Kelin Li; Stacey L McDonald; Quyen Nguyen; Andrew J Perkowski; Cameron W Pharr; Ben Gold; Julia Roberts; Kathrine McAulay; Kohta Saito; Selin Somersan Karakaya; Prisca Elis Javidnia; Esther Porras de Francisco; Manuel Marin Amieva; Sara Palomo Dı Az; Alfonso Mendoza Losana; Matthew Zimmerman; Hsin-Pin Ho Liang; Jun Zhang; Veronique Dartois; Stéphanie Sans; Sophie Lagrange; Laurent Goullieux; Christine Roubert; Carl Nathan; Jeffrey Aubé
Journal:  ACS Infect Dis       Date:  2019-06-11       Impact factor: 5.084

Review 5.  Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?

Authors:  Ronald Domalaon; Temilolu Idowu; George G Zhanel; Frank Schweizer
Journal:  Clin Microbiol Rev       Date:  2018-03-14       Impact factor: 26.132

6.  Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals.

Authors:  J G Christenson; K K Chan; R Cleeland; B Dix-Holzknecht; H H Farrish; I H Patel; A Specian
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

Review 7.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

8.  Relationship between structure and convulsant properties of some beta-lactam antibiotics following intracerebroventricular microinjection in rats.

Authors:  A De Sarro; D Ammendola; M Zappala; S Grasso; G B De Sarro
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 9.  Future directions in antimicrobial chemotherapy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

Review 10.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.